Physician profile
Vikas Kumar Singh
NPI 1124375134
$27,521.81
in general payments reported to CMS, 2019-2025
66 companies · $4,589 in 2025
The $4,589 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $870 · 2021: $2,217 · 2022: $3,362 · 2023: $12K · 2024: $3,636 · 2025: $4,589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,180 · Consulting Fee: $7,164 · Food and Beverage: $3,224 · Travel and Lodging: $678 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,180.00 |
| Consulting Fee | $7,163.75 |
| Food and Beverage | $3,224.37 |
| Travel and Lodging | $677.79 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $9,371.71 | 2020-2023 | Bavencio |
| Eisai INC. | $4,213.86 | 2020-2025 | |
| Seagen INC. | $3,296.87 | 2019-2023 | Padcev |
| Astrazeneca Pharmaceuticals LP | $2,435.46 | 2019-2025 | Imfinzi, Lynparza, Tagrisso |
| Astellas Pharma Global Development | $1,992.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $953.75 | 2023 | |
| Astellas Pharma US INC | $745.58 | 2019-2025 | Padcev, Vyloy, Xospata |
| Novartis Pharmaceuticals Corporation | $371.86 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $350.32 | 2019-2025 | |
| Amgen INC. | $329.90 | 2019-2022 | |
| Pfizer INC. | $250.72 | 2019-2025 | |
| Chiesi USA, INC. | $240.66 | 2020 | |
| Medtronic, INC. | $189.71 | 2022 | |
| Genmab U.S., INC. | $179.45 | 2022-2024 | Epkinly, Tivdak |
| Philips North America LLC | $167.26 | 2023 |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $148.55 | 2019-2024 | Rybrevant, Erleada, Balversa |
| Lilly USA, LLC | $126.26 | 2019-2021 | |
| Genentech USA, INC. | $115.31 | 2022-2025 | Polivy, Columvi, Venclexta |
| Sumitomo Pharma America, INC. | $112.01 | 2023-2025 | Orgovyx |
| Cardiovascular Systems INC. | $100.30 | 2019-2022 | |
| Incyte Corporation | $95.75 | 2019-2024 | Monjuvi, Pemazyre |
| Regeneron Healthcare Solutions, INC. | $82.32 | 2019-2024 | Libtayo |
| Foundation Medicine, INC. | $80.08 | 2019-2020 | |
| Novo Nordisk INC | $79.60 | 2019-2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $79.48 | 2019-2023 | Opdualag |
| Jazz Pharmaceuticals INC. | $78.02 | 2019-2024 | |
| Gilead Sciences, INC. | $75.06 | 2022-2024 | Trodelvy |
| Daiichi Sankyo INC. | $74.09 | 2023-2025 | Enhertu |
| Sobi, INC | $71.69 | 2022-2024 | |
| Abbvie INC. | $68.36 | 2024-2025 | |
| Blueprint Medicines Corporation | $65.89 | 2023-2025 | Ayvakit |
| Tempus Ai, INC | $60.09 | 2024 | |
| Celgene Corporation | $57.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.91 | 2020-2023 | Gilotrif |
| Genzyme Corporation | $56.32 | 2019-2023 | |
| Tersera Therapeutics LLC | $50.88 | 2023-2024 | Zoladex |
| Puma Biotechnology, INC. | $50.85 | 2023-2024 | |
| Angiodynamics, INC. | $49.76 | 2024-2025 | Auryon Laser System 100-120 Vac, Alphavac |
| Servier Pharmaceuticals LLC | $49.04 | 2023-2025 | |
| Taiho Oncology, INC. | $48.25 | 2022-2023 | |
| Stemline Therapeutics INC. | $41.23 | 2023-2024 | Orserdu |
| Takeda Pharmaceuticals U.S.A., INC. | $40.54 | 2023-2024 | Alunbrig, Fruzaqla |
| Boston Scientific Corporation | $39.16 | 2021-2022 | |
| Abbott Laboratories | $37.78 | 2021-2023 | Diamondback Coronary |
| Leadiant Biosciences, INC. | $36.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $22.70 | 2023 | Yonsa, Odomzo |
| Rigel Pharmaceuticals, INC. | $21.70 | 2022-2024 | Tavalisse, Rezlidhia |
| Coherus Oncology, INC. | $20.44 | 2023 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Verastem, INC. | $17.86 | 2020 | |
| Livanova USA, INC. | $17.47 | 2023 | Lifesparc |
| Apellis Pharmaceuticals, INC. | $17.30 | 2023 | Empaveli |
| Recordati_rare_diseases_inc. | $16.38 | 2023 | Panhematin |
| Cardinal Health 200 LLC | $16.19 | 2021 | |
| Array Biopharma INC | $15.59 | 2024 | Braftovi, Lorbrena, Mektovi |
| Pharmacosmos Therapeutics INC. | $15.57 | 2024 | Monoferric |
| Novocure INC. | $15.39 | 2024 | Optune Lua (Novottf-200t) |
| Springworks Therapeutics, INC. | $14.52 | 2024 | Ogsiveo |
| Ipsen Biopharmaceuticals, INC | $13.35 | 2022 | |
| Alexion Pharmaceuticals, INC. | $13.20 | 2019 | |
| Fennec Pharmaceuticals, INC. | $13.12 | 2024 | Pedmark |
| Karyopharm Therapeutics INC. | $13.05 | 2020 | |
| W. L. Gore & Associates, INC. | $12.06 | 2020 | |
| Secura Bio, INC. | $9.80 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.